LDDM (Large Drug Discovery Model) is introduced, a generative framework that supports a range of drug discovery tasks, including constrained and unconstrained docking, fragment linking and growing, and de novo design, and a programmable design algorithm that enables accurate design of synthetically accessible compounds...
Ilia Igashov, Arne Schneuing, Adrian W. Dobbelstein et al.· bioRxiv· 0 citations
This pipeline identified 6 known and 43 novel CRBN-pomalidomide binders, including orthogonally validated hits that provide privileged starting points for MGD development, and expects this binding-focused workflow to be applicable to other MGD-E3 ligase systems, potentially extending the scope of this emerging drug cla...
Pius Galli, Shuhao Xiao, Y. Meng et al.· Nature Biotechnology· 1 citation
The concept of mimic antibodies–antibodies that recapitulate the binding mode of a target’s cognate ligand is investigated and established as a promising strategy for rational antibody selection, engineering, and design, with broad implications for therapeutic antibody development and drug discovery.
Brennan Abanades, Joanan López-Morales, Ivana Tanasijević et al.· mAbs· 2 citations
The Human Bindome is presented, a proteome-scale atlas of high-confidence in silico protein binder candidates that positions the Bindome as a resource of genetically encodable perturbagens for site-specific, modular control of protein function.
Julius Wenckstern, Anna M. Díaz-Rovira, Julia A. Kuhn et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
